Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Evaluation of Factors Influencing Use of RoActemra as Monotherapy in Rheumatoid Arthritis Patients in a Real Life Setting - ACT SOLO

Trial Profile

Evaluation of Factors Influencing Use of RoActemra as Monotherapy in Rheumatoid Arthritis Patients in a Real Life Setting - ACT SOLO

Status: Completed
Phase of Trial: Phase IV

Latest Information Update: 07 Nov 2021

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Tocilizumab (Primary)
  • Indications Rheumatoid arthritis
  • Focus Therapeutic Use
  • Acronyms ACT-SOLO
  • Sponsors Roche
  • Most Recent Events

    • 08 Nov 2017 Results of pooled analysis from SPARE-1 and Act-solo studies assessing factors influencing the use of TCZ in Mono or in combination with DMARDs (Combo) in real-life practice in RA patients, were presented at the 81st American College of Rheumatology and the 52nd Association of Rheumatology Health Professionals Annual Scientific Meeting.
    • 12 Oct 2017 Results (n=884) of pooled analysis from SPARE-1 and Act-solo studies, presented at the 20th Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research.
    • 17 Jun 2017 Results of pooled analysis (n=1494) of three observational studies (PEPS, Spare-1 and Act-solo), presented at the 18th Annual Congress of the European League Against Rheumatism.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top